Pharmacokinetics, absorption, distribution, metabolism and excretion of the MEK inhibitor zapnometinib in rats

Zapnometinib is a MEK inhibitor currently under clinical development for the treatment of COVID-19 and influenza. Zapnometinib has both antiviral and immunomodulatory effects. Information concerning the absorption, distribution, metabolism, and excretion of the compound following single oral doses o...

Descripción completa

Detalles Bibliográficos
Autores principales: Füll, Yvonne, Wallasch, Christian, Hilton, Ashley, Planz, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760738/
https://www.ncbi.nlm.nih.gov/pubmed/36545320
http://dx.doi.org/10.3389/fphar.2022.1050193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760738/
https://www.ncbi.nlm.nih.gov/pubmed/36545320
http://dx.doi.org/10.3389/fphar.2022.1050193

Ejemplares similares